Find the right fit for you - faster
Get tailored insights about working at ConjuChem in one quick step.
ConjuChem Snapshot
ConjuChem Biotechnologies developed long-acting peptide-based pharmaceuticals to treat diseases such as congestive heart failure, diabetes, HIV/AIDS, and human growth deficiencies. The company, primarily a research and development operation, fostered a technology to bind peptides to albumin in order to extend the half life of drugs from minutes to days. Its lead candidate, Exendin-4, which was considered as a treatment for type 2 diabetes, was in clinical trials in Europe and North America. As a result of financial pressures, ConjuChem voluntarily filed for bankruptcy and prepared to liquidate its assets in mid-2010.
